← brief for 2026-08-27 · Slowing decline

Real-world long-term outcomes and safety of avacopan for antineutrophil cytoplasmic antibody-associated vasculitis with advanced renal dysfunction: a multicenter cohort study (4U-AAV Study)

Key takeaways

Avacopan is a drug for ANCA vasculitis, a disease where the immune system attacks small blood vessels, including those in the kidney. This study followed people who took it in normal care, not in a trial, and focused on those whose kidneys were already badly damaged. It tracked how they did over the long term and what side effects came up. Because doctors chose who got the drug, this shows a link between the drug and the outcomes, not proof that the drug caused them.

Who did this work

Kumiko Muta (University of Nagasaki) · Kenta Torigoe (University of Nagasaki) · Emi Hasegawa (University of Occupational and Environmental Health Japan) · Mineaki Kitamura (University of Nagasaki) · Akihiro Fukuda (Oita University) · Masao Kikuchi (University of Miyazaki) · Tetsu Miyamoto (University of Occupational and Environmental Health Japan) · Takeshi Nakata (Oita University) · Naoya Fukunaga (Oita Prefectural Hospital) · Shoichi Fujimoto (University of Miyazaki) · Tomoya Nishino (University of Nagasaki)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-08-26
https://doi.org/10.1007/s10157-026-02936-4